0001062993-18-003527.txt : 20180823
0001062993-18-003527.hdr.sgml : 20180823
20180823203631
ACCESSION NUMBER: 0001062993-18-003527
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180822
FILED AS OF DATE: 20180823
DATE AS OF CHANGE: 20180823
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wegman Mark N
CENTRAL INDEX KEY: 0001405235
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 181035717
MAIL ADDRESS:
STREET 1: 43 OVERLOOK ROAD
CITY: OSSINING
STATE: NY
ZIP: 10562
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 5165937000
MAIL ADDRESS:
STREET 1: 35 WILBUR STREET
CITY: LYNBROOK
STATE: NY
ZIP: 11563
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2018-08-22
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001405235
Wegman Mark N
C/O BIOSPECIFICS TECHNOLOGIES CORP.
35 WILBUR STREET
LYNBROOK
NY
11563
1
0
0
0
Common Stock, $0.001 par value
2018-08-22
4
S
0
3802
52.7073
D
76470
D
Common Stock, $0.001 par value
2018-08-23
4
S
0
4698
52.5604
D
71772
D
The selling price of $52.7073 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $52.26 to $53.14. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The selling price of $52.5604 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $51.02 to $52.82. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Mark Wegman by Carl A. Valenstein, attorney- in-fact
2018-08-23